Summary: has introduced NeuroQuant v5.0, pending FDA approval, enhancing neuroimaging precision for diagnosing and monitoring neurological disorders.

Key Takeaways

  1. NeuroQuant v5.0, which is awaiting FDA approval, can enhance accuracy in diagnosing and monitoring neurological disorders.
  2. This update enables identification and evaluation of cerebral microhemorrhages, aiding in diagnosing brain conditions.

—————————————————————————————————————————————————————————— has introduced a new version of its NeuroQuant software, version 5.0, which is currently pending U.S. FDA 510(k) approval. This update enhances the precision of neuroimaging for diagnosing and monitoring neurological disorders, according to company officials.

This latest update to NeuroQuant will expand the use of the software to support identification and evaluation of cerebral microhemorrhages on susceptibility-sensitive MRI sequences—small focal brain lesions commonly found in patients with traumatic brain injuries, cerebral amyloid deposition diseases including cerebral amyloid angiopathy and Alzheimer’s disease, as well as patients with amyloid related imaging abnormalities.

Precise Brain Health Monitoring

“Our upcoming NeuroQuant® v5.0 application empowers healthcare professionals with precise data to inform diagnoses and monitor brain health,” says Brandon Steach, head of product at “This innovation underscores our commitment to advancing neurological care for radiologists, neurologists, researchers, and patients alike.”’s chief technology officer Nate White, PhD, also spoke out about the latest version of the software, commenting: “Since the first commercial launch of NeuroQuant in 2006, Cortechs continues to lead our industry, driving transformation through pioneering initiatives and fueling innovation in imaging-based AI technologies. The release of NeuroQuant v5.0 strengthens our commitment to staying ahead of the curve and continuously pushing boundaries to provide AI-driven solutions to optimize patient care.”